Cellebrite DI Ltd. (NASDAQ:CLBT) Sees Significant Increase in Short Interest

Key Points

• Cellebrite DI Ltd. experienced a significant increase in short interest, rising by 42.1% in August to 5,160,000 shares.
• The company reported earnings per share (EPS) of $0.12 for the quarter, exceeding estimates, while revenue was up 18.4% year-over-year, totaling $113.28 million.
• Brokerages have varied outlooks on CBLT, with five analysts rating the stock as Buy and an average price target of $22.40.

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) was the target of a large growth in short interest in August. As of August 15th, there was short interest totaling 5,160,000 shares, a growth of 42.1% from the July 31st total of 3,630,000 shares. Based on an average daily volume of 1,760,000 shares, the short-interest ratio is presently 2.9 days. Approximately 4.7% of the company's stock are short sold. Approximately 4.7% of the company's stock are short sold. Based on an average daily volume of 1,760,000 shares, the short-interest ratio is presently 2.9 days.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Needham & Company LLC reduced their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Wall Street Zen downgraded shares of Cellebrite DI from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Lake Street Capital lowered their target price on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $22.40.

Cellebrite DI Trading Down 2.2%

Shares of CLBT stock traded down $0.38 during trading on Friday, reaching $16.80. 1,572,538 shares of the company's stock traded hands, compared to its average volume of 2,185,428. The company has a market capitalization of $4.02 billion, a P/E ratio of -22.11, a PEG ratio of 3.12 and a beta of 1.28. The firm's 50-day moving average is $15.18 and its 200 day moving average is $16.97. Cellebrite DI has a 1 year low of $13.10 and a 1 year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.01. The company had revenue of $113.28 million for the quarter, compared to analysts' expectations of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. Cellebrite DI's revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts predict that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Trading of Cellebrite DI

A number of institutional investors have recently modified their holdings of the business. OneDigital Investment Advisors LLC lifted its stake in shares of Cellebrite DI by 2.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock valued at $556,000 after buying an additional 688 shares in the last quarter. Signaturefd LLC lifted its stake in Cellebrite DI by 68.3% in the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company's stock worth $32,000 after purchasing an additional 819 shares in the last quarter. SkyView Investment Advisors LLC lifted its stake in Cellebrite DI by 2.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company's stock worth $597,000 after purchasing an additional 970 shares in the last quarter. Bosun Asset Management LLC lifted its stake in Cellebrite DI by 2.5% in the 1st quarter. Bosun Asset Management LLC now owns 44,376 shares of the company's stock worth $862,000 after purchasing an additional 1,069 shares in the last quarter. Finally, Fox Run Management L.L.C. lifted its stake in Cellebrite DI by 3.9% in the 2nd quarter. Fox Run Management L.L.C. now owns 30,359 shares of the company's stock worth $486,000 after purchasing an additional 1,127 shares in the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.